CTRI/2021/10/037520进行中（未招募）4 期
A Postmarketing, Phase 4, Multicentre, Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma With Eosinophilic Phenotype in India - FAST
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients 18 to 75 years of age inclusive, at the time of signing the informed consent
- •2. Patients with physicianÂ?fs confirmed diagnosis of severe asthma with an eosinophilic phenotype, ie, diagnosis of severe asthma in preceding at least 12 months, with an eosinophil count of .300 cells/Æ?Ã?L at screening, requiring treatment with high-dose ICS ( >500 Æ?Ã?g fluticasone propionate dry powder formulation, or >800 Æ?Ã?g budesonide dry powder formulation, or equivalent total daily dose) and a LABA as maintenance treatment for at least 3 months prior to enrolment
- •3. A decreased lung function with prebronchodilator (Pre-BD) forced expiratory volume in 1 second (FEV1) of <80% predicted, demonstrated by spirometry at screening
- •4. At least 2 documented asthma exacerbations in the preceeding12 months, except in 30 days before the date of informed consent, that required the use of a systemic corticosteroid or temporary increase from the patientâ??s usual maintenance dose of OCS
- •5. Documented postbronchodilator (post-BD) reversibility in FEV1 of .12% and .200 mL in FEV1 within 12 months before first dose. If historical documentation is not available, reversibility must be demonstrated and documented at screening or Day 1 before first dose
- •6. Benralizumab naive patients who have not previously received Benralizumab prior to the start of this study
- •7. Patients who are willing and capable of giving signed informed consent as described in Appendix A, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
排除标准
- •Exclusion Criteria:
- •Patients will be excluded from the study if any of the following criteria apply:
- •1. Clinically important pulmonary disease other than asthma (eg, active lung infection, chronic obstructive pulmonary disease, bronchiectasis, pulmonary fibrosis, cystic fibrosis etc.) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome), which can confound the outcome assessment
- •2. Patients currently enrolled in an interventional clinical study in parallel including those with any biologic treatment
- •3. Patients who have received any biologic within 30 days prior to the date of informed consent.
- •4. Known history of allergy or reaction to the benralizumab formulation or excipients (L-histidine, L-histidine hydrochloride monohydrate, á-trehalose dihydrate, polysorbate 20, water for injection)
- •5. History of anaphylaxis to any biologic therapy
- •6. A helminthic parasitic infection diagnosed within 24 weeks before the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy
- •7. Acute asthma exacerbation 30 days before the date informed consent
- •8. Acute asthma exacerbation between screening and first dose of study dose administration.
- •9. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days before the date informed consent
- •10. Patients with malignancy within 5 years prior to enrolment, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, basal, or squamous cell carcinoma or non-melanomatous skin cancer with active or recent malignancy
- •11. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis, which, in the opinion of the investigator, may put the participant at risk because of his/her participation in the study
- •12. History of current alcohol, drug, or chemical abuse or past abuse that would impair or risk the participantâ??s full participation in the study, in the opinion of the investigator
- •13. Female patients who are pregnant or lactating or planning a family during the study period.
研究者
相似试验
已完成
4 期
A study to examine the side effects and benefits of Hetero - AdalimumabCTRI/2018/06/014661Hetero Biopharma Limited200
尚未招募
4 期
ong term Safety and efficacy of Trastuzumab in Indian female patients with HER2+ breast cancer.CTRI/2024/01/061144Hetero Biopharma Limited
招募中
4 期
Study to assess the Safety and efficacy of Hetero tenecteplase in the treatment of Myocardial infarction.CTRI/2024/03/063694Hetero Biopharma Limited
尚未招募
不适用
A multicentre, post-marketing, prospective, observational study to evaluate the safety and performance of the Apex Total Knee Replacement system.OsteoarthritisACTRN12618000441213Global Orthopaedic Technology1,000
已完成
4 期
Post marketing study to assess side effects, antibody development and effectiveness of Hetero-RituximabCTRI/2018/03/012588Hetero Drugs Limited200